{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:37:31Z","timestamp":1792121851425,"version":"4.4.0"},"reference-count":28,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Concizumab is an anti\u2013tissue factor pathway inhibitor (TFPI) monoclonal antibody intended for once-daily subcutaneous prophylactic treatment for people with hemophilia A or B with and without inhibitors. Results from the phase 3 explorer7 study confirmed superiority of concizumab prophylaxis over no prophylaxis in reducing the annualized bleeding rate (ABR) in people with hemophilia A or B with inhibitors (HAwI\/HBwI). Male patients aged \u226512 years were randomized 1:2 to no prophylaxis (group 1) or concizumab prophylaxis (group 2), or nonrandomly allocated to concizumab prophylaxis (groups 3 and 4). After \u226524 weeks of treatment, patients in group 1 could switch to concizumab prophylaxis. At the 56-week cutoff (defined as when all patients in groups 2-4 had completed the visit at 56 weeks or permanently discontinued treatment), bleed-related efficacy, pharmacokinetics and pharmacodynamics, and safety were assessed. Of the 133 patients enrolled (HAwI, n = 80; HBwI, n = 53), 114 received concizumab prophylaxis (groups 2-4) and 19 were randomized to no prophylaxis (group 1). After \u226524 weeks, 13 patients from group 1 switched to concizumab. Median ABR for treated spontaneous and traumatic bleeding episodes in patients receiving concizumab was 0.8 (interquartile range [IQR], 0.0-3.2) at the 56-week cutoff, consistent with the low bleeding rates (median ABR, 0.0; IQR, 0.0-3.3) at the 32-week cutoff. Concizumab and free-TFPI concentration remained stable over time. No new safety concerns were reported. Longer-term (\u22651 year) efficacy and safety results of concizumab prophylaxis for HAwI\/HBwI were consistent with the 32-week cutoff results in explorer7. This trial was registered at www.clinicaltrials.gov as #NCT04083781.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018264","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T21:22:53Z","timestamp":1767820973000},"page":"1854-1863","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Concizumab in hemophilia with inhibitors: longer-term efficacy and safety results from the phase 3 explorer7 study"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5781-7669","authenticated-orcid":false,"given":"Johnny","family":"Mahlangu","sequence":"first","affiliation":[{"name":"1Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3532-2336","authenticated-orcid":false,"given":"Ana","family":"Boban","sequence":"additional","affiliation":[{"name":"2Hemophilia Center, Department of Hematology, University Hospital Centre Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bruzelius","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Solna, Karolinska Institute, Stockholm, Sweden"},{"name":"4Department of Hematology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4973-1317","authenticated-orcid":false,"given":"Giancarlo","family":"Castaman","sequence":"additional","affiliation":[{"name":"5Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kingsley","family":"Hampton","sequence":"additional","affiliation":[{"name":"6Department of Cardiovascular Science, University of Sheffield, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Knoebl","sequence":"additional","affiliation":[{"name":"7Division of Hematology and Hemostasis, Department of Medicine, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Lebreton","sequence":"additional","affiliation":[{"name":"8Hemophilia Comprehensive Care Center, Centre Hospitalier Universitaire Clermont-Ferrand, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5849-7377","authenticated-orcid":false,"given":"Silvia","family":"Linari","sequence":"additional","affiliation":[{"name":"5Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2407-3901","authenticated-orcid":false,"given":"Francisco-Jos\u00e9","family":"L\u00f3pez-Jaime","sequence":"additional","affiliation":[{"name":"9Hospital Universitario Regional de M\u00e1laga, El Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga, M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Martins Mazini Tavares","sequence":"additional","affiliation":[{"name":"10Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Salim","family":"Nekkal","sequence":"additional","affiliation":[{"name":"11Hemophilia Care Center, University Hospital Medical Center Beni Messous, Algiers, Algeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[{"name":"12Department of Pediatrics, Nara Medical University, Kashihara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalie","family":"Rhode H\u00f8gh Nielsen","sequence":"additional","affiliation":[{"name":"10Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2821-7159","authenticated-orcid":false,"given":"Amy","family":"Shapiro","sequence":"additional","affiliation":[{"name":"13Indiana Hemophilia and Thrombosis Center, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4843-7805","authenticated-orcid":false,"given":"Roseline","family":"d\u2019Oiron","sequence":"additional","affiliation":[{"name":"14Reference Center for Hemophilia and Rare Bleeding Disorders, H\u00f4pital Bic\u00eatre Assistance Publique\u2013H\u00f4pitaux de Paris, Universit\u00e9 Paris-Saclay, Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"issue":"suppl 6","key":"2026032014062604900_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"5","key":"2026032014062604900_bib2","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial","volume":"13","author":"Chowdary","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"suppl 1","key":"2026032014062604900_bib3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2516.2009.02156.x","article-title":"Venous access in haemophilic children: choice and management","volume":"16","author":"Santagostino","year":"2010","journal-title":"Haemophilia"},{"issue":"4","key":"2026032014062604900_bib4","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ymthe.2019.11.006","article-title":"A molecular revolution in the treatment of hemophilia","volume":"28","author":"Butterfield","year":"2020","journal-title":"Mol Ther"},{"issue":"5","key":"2026032014062604900_bib5","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/ejh.14277","article-title":"Disease and treatment burden of patients with haemophilia entering the explorer6 non-interventional study","volume":"113","author":"Windyga","year":"2024","journal-title":"Eur J Haematol"},{"issue":"4","key":"2026032014062604900_bib6","doi-asserted-by":"crossref","first-page":"102476","DOI":"10.1016\/j.rpth.2024.102476","article-title":"Concizumab prophylaxis in persons with hemophilia A or B with inhibitors: patient-reported outcome results from the phase 3 explorer7 study","volume":"8","author":"Tran","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"2026032014062604900_bib7","first-page":"S457","article-title":"A usability study assessing handling and preference of the concizumab pen-injector in patients with haemophilia and caregivers","volume":"45","author":"Rasmussen","year":"2023","journal-title":"Hematol Transfus Call Ther"},{"key":"2026032014062604900_bib8","unstructured":"Alhemo\n          . Summary of product characteristics. EMA 2025. Accessed 8 January 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/alhemo-epar-product-information_en.pdf."},{"key":"2026032014062604900_bib9","unstructured":"Alhemo\n          . Prescribing information. U.S. Food and Drug Adminstration 2024. Accessed 8 January 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761315s000lbl.pdf."},{"key":"2026032014062604900_bib10","volume-title":"Report on the Deliberation Results","year":"2013"},{"issue":"9","key":"2026032014062604900_bib11","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"Matsushita","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"2026032014062604900_bib12","doi-asserted-by":"crossref","first-page":"e891","DOI":"10.1016\/S2352-3026(24)00307-7","article-title":"Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial","volume":"11","author":"Chowdary","year":"2024","journal-title":"Lancet Haematol"},{"issue":"S1","key":"2026032014062604900_bib13","first-page":"24","article-title":"Longer-term concizumab prophylaxis in patients with haemophilia A or B with inhibitors: \u22651-year (56-week cut-off) efficacy and safety results from the phase 3 explorer7 Trial","volume":"29","author":"Mathias","year":"2023","journal-title":"Haemophilia"},{"issue":"S2","key":"2026032014062604900_bib14","first-page":"102503","article-title":"Management of breakthrough bleeding episodes in the phase 3 concizumab studies","volume":"8","author":"Mahlangu","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"issue":"suppl 1","key":"2026032014062604900_bib15","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/blood-2024-209759","article-title":"Annualized bleeding rates in patients with hemophilia A or B and inhibitors with and without target joints at baseline: results from the concizumab phase 3 Explorer7 study","volume":"144","author":"Shapiro","year":"2024","journal-title":"Blood"},{"issue":"11","key":"2026032014062604900_bib16","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"suppl 1","key":"2026032014062604900_bib17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2023-179739","article-title":"Surgical procedures and hemostatic outcome in patients with hemophilia receiving concizumab prophylaxis during the phase 3 explorer7 and explorer8 Trials","volume":"142","author":"Chan","year":"2023","journal-title":"Blood"},{"key":"2026032014062604900_bib18","unstructured":"ActiGraph\n          . ActiGraph\u2122 LLC. Accessed 24 November 2024. https:\/\/theactigraph.com\/."},{"issue":"S2","key":"2026032014062604900_bib19","first-page":"3","article-title":"Active lifestyle in patients with haemophilia A or B with and without active inhibitors on once-daily subcutaneous concizumab prophylaxis: results from the phase 3 explorer7 and explorer8 trials","volume":"30","author":"Jim\u00e9nez Yuste","year":"2024","journal-title":"Haemophilia"},{"issue":"4","key":"2026032014062604900_bib20","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1152\/japplphysiol.00026.2015","article-title":"Methods to estimate aspects of physical activity and sedentary behavior from high-frequency wrist accelerometer measurements","volume":"119","author":"Staudenmayer","year":"2015","journal-title":"J Appl Physiol (1985)"},{"key":"2026032014062604900_bib21","unstructured":"National Hemophilia Foundation\n          . Playing It Safe: Bleeding Disorders, Sports and Exercise. Accessed 26 June 2025. https:\/\/www.bleeding.org\/sites\/default\/files\/document\/files\/playing-it-safe_0.pdf."},{"issue":"6","key":"2026032014062604900_bib22","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/hae.12959","article-title":"Long-term effects of joint bleeding before starting prophylaxis in severe haemophilia","volume":"22","author":"Nijdam","year":"2016","journal-title":"Haemophilia"},{"issue":"1","key":"2026032014062604900_bib23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12955-018-0908-9","article-title":"The impact of severe haemophilia and the presence of target joints on health-related quality-of-life","volume":"16","author":"O'Hara","year":"2018","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"2026032014062604900_bib24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13052-015-0116-8","article-title":"Desensitization and immune tolerance induction in children with severe factor IX deficiency; inhibitors and adverse reactions to replacement therapy: a case-report and literature review","volume":"41","author":"Bon","year":"2015","journal-title":"Ital J Pediatr"},{"issue":"3","key":"2026032014062604900_bib25","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1365-2516.2003.00772.x","article-title":"Management of haemophilia B inhibitor patients with anaphylactic reactions to FIX concentrates","volume":"9","author":"Shibata","year":"2003","journal-title":"Haemophilia"},{"issue":"4","key":"2026032014062604900_bib26","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/jcm6040046","article-title":"Treatment and prevention of bleeds in haemophilia patients with inhibitors to factor VIII\/IX","volume":"6","author":"Rocino","year":"2017","journal-title":"J Clin Med"},{"key":"2026032014062604900_bib27","unstructured":"European Medicines Agency\n          . Alhemo. Accessed 8 January 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/alhemo#product-details."},{"issue":"4","key":"2026032014062604900_bib28","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/hae.15070","article-title":"Minimal interference of concizumab with standard clinical coagulation laboratory assays - an in vitro study","volume":"30","author":"Augustsson","year":"2024","journal-title":"Haemophilia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/6\/1854\/2508075\/blooda_adv-2025-018264-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/6\/1854\/2508075\/blooda_adv-2025-018264-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T18:06:35Z","timestamp":1774029995000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/6\/1854\/565889\/Concizumab-in-hemophilia-with-inhibitors-longer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,3,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018264","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,24]]},"published":{"date-parts":[[2026,3,11]]}}}